Home LiteratureArticle Details
PMID: 19441105 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis.

Hepatology (Baltimore, Md.) ·Vol. 50 ·No. 1 ·2009-07-00 ·Pages 230-43

Weng HL, Liu Y, Chen JL, Huang T, Xu LJ, Godoy P, Hu JH, Zhou C, Stickel F, Marx A, Bohle RM, Zimmer V, Lammert F, Mueller S, Gigou M, Samuel D, Mertens PR, Singer MV, Seitz HK, Dooley S

Abstract

It is unknown whether transforming growth factor beta1 (TGF-beta1) signaling uniformly participates in fibrogenic chronic liver diseases, irrespective of the underlying origin, or if other cytokines such as interleukin (IL)-13 share in fibrogenesis (e.g., due to regulatory effects on type I pro-collagen expression). TGF-beta1 signaling events were scored in 396 liver tissue samples from patients with diverse chronic liver diseases, including hepatitis B virus (HBV), hepatitis C virus (HCV), Schistosoma japonicum infection, and steatosis/steatohepatitis. Phospho-Smad2 staining correlated significantly with fibrotic stage in patients with HBV infection (n = 112, P < 0.001) and steatosis/steatohepatitis (n = 120, P < 0.01), but not in patients with HCV infection (n = 77, P > 0.05). In tissue with HBx protein expression, phospho-Smad2 was detectable, suggesting a functional link between viral protein expression and TGF-beta1 signaling. For IL-13, immunostaining correlated with fibrotic stage in patients with HCV infection and steatosis/steatohepatitis. IL-13 protein was more abundant in liver tissue lysates from three HCV patients compared with controls, as were IL-13 serum levels in 68 patients with chronic HCV infection compared with 20 healthy volunteers (72.87 +/- 26.38 versus 45.41 +/- 3.73, P < 0.001). Immunohistochemistry results suggest that IL-13-mediated liver fibrogenesis may take place in the absence of phospho-signal transducer and activator of transcription protein 6 signaling. In a subgroup of patients with advanced liver fibrosis (stage > or =3), neither TGF-beta nor IL-13 signaling was detectable. Depending on the cause of liver damage, a predominance of TGF-beta or IL-13 signaling is found. TGF-beta1 predominance is detected in HBV-related liver fibrogenesis and IL-13 predominance in chronic HCV infection. In some instances, the underlying fibrogenic mediator remains enigmatic.

MeSH Terms
Humans In Vitro Techniques Interleukin-13/physiology Liver Cirrhosis/etiology Liver Diseases/etiology Transforming Growth Factor beta1/physiology
Chemicals
Interleukin-13 Transforming Growth Factor beta1
Authors & Affiliations
20 authors, click to expand affiliations / ORCID
Weng Hong-Lei
Molecular Alcohol Research in Gastroenterology, Department of Medicine II, Faculty of Medicine at Mannheim, University of Heidelberg, Germany. [email protected]
Liu Yan
Chen Jia-Lin
Huang Tong
Xu Li-Jun
Godoy Patricio
Hu Jun-Hua
Zhou Cheng
Stickel Felix
Marx Alexander
Bohle Rainer M
Zimmer Vincent
Lammert Frank
Mueller Sebastian
Gigou Michelle
Samuel Didier
Mertens Peter R
Singer Manfred V
Seitz Helmut K
Dooley Steven
Article Info
Journal
Hepatology (Baltimore, Md.)
Abbr.
Hepatology
ISSN
1527-3350
Published
2009-07-00
Pages
230-43
Language
English
Region
United States
NLM ID
8302946
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]